Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

inotuzumab ozogamicin

- PMLiVE

Valneva and Pfizer initiate phase 3 Lyme disease vaccine study

VLA15 is the only Lyme disease vaccine candidate currently in clinical development

- PMLiVE

Pfizer and BioNTech initiate phase 2 study of ‘enhanced’ COVID-19 vaccine

The vaccine is based on a version of the spike protein that the companies hope will offer better and broader protection against the virus

- PMLiVE

Pfizer and BioNTech speak out against CureVac suit over patents for COVID-19 vaccines

The civil suit claims that once CureVac had withdrawn its vaccine candidate, the company was unable to garner 50% efficacy in a late-stage trial

- PMLiVE

NICE recommends Rhythm Pharmaceuticals’ Imcivree for severe obesity and hyperphagia

The treatment will be funded and available for use within 90 days in the NHS

- PMLiVE

Bristol Myers Squibb announces NICE recommendation for Opdivo plus Yervoy to treat unresectable malignant pleural mesothelioma

The treatment combination is the first immunotherapy of its kind in over ten years to be made available via the NHS

- PMLiVE

NICE recommends Novartis’ Piqray in combination with Faslodex for advanced breast cancer patients

Around 2,800 breast cancer patients in England and Wales could benefit from the treatment

- PMLiVE

GSK creates new consumer healthcare business, Haleon

Haleon, whose brand portfolio will include Sensodyne toothpaste and Panadol painkillers, is the combination of the consumer health businesses of GSK and Pfizer

- PMLiVE

Bristol Myers Squibb’s Opdivo given NICE recommendation for urothelial cancer treatment

The treatment will be available on the NHS as an adjuvant treatment for those at high-risk of recurrence

- PMLiVE

Pfizer’s Paxlovid given FDA permission to be prescribed by US pharmacists

Under the Emergency Use Authorisation revision, pharmacists will be able to prescribe the COVID-19 treatment to patients, providing they meet certain conditions

- PMLiVE

Pfizer announces commitment to achieve Net-Zero Standard by 2040

The company hopes to achieve the net-zero target ten years earlier than the expectations of the Net-Zero Standard

- PMLiVE

NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia

The recommendation makes Scemblix the first treatment in its class to be authorised in Britain

- PMLiVE

Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government

The companies will supply 105 million doses, which may include adult Omicron-adapted COVID-19 vaccines, subject to FDA authorisation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links